Introduction: Sotalol and verapamil alone reduce reentry incidence during ventricular fibrillation (VF). We tested whether the combination of these two drugs had a synergistic effect on initiation, maintenance, and termination of VF.

Methods: Six open-chest pigs received intravenous sotalol (1.5 mg/kg) followed by verapamil (0.136 mg/kg). VF threshold (VFT) was determined by a burst pacing protocol. Two 20 seconds episodes of VF were recorded from a 21 × 24 unipolar electrode plaque on the lateral posterior left ventricular epicardium before and after each drug. VF activation patterns were quantified. The duration of long duration VF (LDVF) maintenance was compared to our previously published data.

Results: Sotalol alone and combined with verapamil significantly increased the VFT from 12.3 ± 4.1 to 20.3 ± 7.1 and 26.7 ± 8.6 mA compared with baseline (P < .05). Sotalol decreased the number of wavefronts by 20%, VF activation rate by 17% and conduction velocity 11%, while the addition of verapamil neutralized these effects. Addition of verapamil to sotalol further decreased the fractionation incidence from 14% to 29% and multiplicity from 24% to 31% compared with baseline. The combination of the two drugs increased the VF cycle length, decreased synchronicity, increased regularity index and shortened the duration of LDVF maintenance compared with our previous data of verapamil alone or no drug. Synchronicity index was lower and regularity index was higher in animals in which VF spontaneously terminated earlier than 10 minutes than in animals in which VF terminated longer than 10 minutes.

Conclusion: The combination of sotalol and verapamil increased VFT but accelerated LDVF termination.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945327PMC
http://dx.doi.org/10.1111/1755-5922.12326DOI Listing

Publication Analysis

Top Keywords

sotalol verapamil
8
initiation maintenance
8
maintenance termination
8
ventricular fibrillation
8
effects combination
4
sotalol
4
combination sotalol
4
verapamil
4
verapamil initiation
4
termination ventricular
4

Similar Publications

Article Synopsis
  • Long-QT syndrome type 3 (LQT3) is a cardiac ion channel disorder that increases the risk of dangerous heart rhythms, and this study aimed to create a model using human induced pluripotent stem cells (hiPSCs) to better understand the disease and test potential treatments.!
  • Researchers generated hiPSCs from a patient with LQT3 and a healthy individual, employing CRISPR/Cas9 to introduce the same genetic mutation into healthy cells; all hiPSC lines were then converted into heart cells for analysis.!
  • Both patient-derived and engineered LQT3 heart cells exhibited longer repolarization times, but treatments like mexiletine, nifedipine, and verapamil could effectively alter these
View Article and Find Full Text PDF

Pharmacological characterisation of electrocardiogram J-T interval in conscious Guinea pigs.

Eur J Pharmacol

July 2022

Watarase Research Center, Kyorin Pharmaceutical Co., Ltd., 1848, Nogi, Nogi-machi, Shimotsuga-gun, Tochigi, 329-0114, Japan.

Drug-induced human ether-à-go-go-related gene (hERG) channel block and QT interval prolongation increase torsade de pointes (TdP) risk. However, some drugs block hERG channels and prolong QT interval with low TdP risk, likely because they block additional inward currents. We investigated the utility of J-T interval, a novel biomarker of inward current block and TdP risk, in conscious telemetered guinea pigs.

View Article and Find Full Text PDF

Combined therapy using several antiarrhythmic agents can be useful for treatment of different disorders of cardiac rhythm, including their hazardous and stable forms. It is especially required in case of insufficient efficacy after using one antiarrhythmic agent. As a combined therapy one can use the administration of several preparations e.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!